What one share of Denali Therapeutics holds
Our purpose is to bring the power of biotherapeutics to the whole body, including the brain, by discovering, developing, and delivering medicines for people living with serious diseases.
Denali Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.84 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$2.42 |
| Cash and investments | $5.88 |
| Book value | $5.23 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$13.49 | $0.95 | −$12.15 | — | −$14.65 |
| 2017 | $0.00 | −$5.89 | $0.19 | −$5.31 | — | — |
| 2018 | $1.39 | −$0.39 | $0.04 | $0.50 | — | $5.78 |
| 2019 | $0.28 | −$2.07 | $0.19 | −$1.77 | — | $4.11 |
| 2020 | $2.98 | $0.63 | $0.03 | $3.67 | — | $9.55 |
| 2021 | $0.40 | −$2.39 | $0.07 | −$1.81 | — | $7.87 |
| 2022 | $0.86 | −$2.60 | $0.14 | −$2.09 | — | $7.67 |
| 2023 | $2.41 | −$1.06 | $0.09 | −$2.70 | — | $7.45 |
| 2024 | $0.00 | −$2.57 | $0.10 | −$2.21 | — | $8.53 |
| 2025 | $0.00 | −$2.97 | $0.06 | −$2.44 | — | $6.49 |
Common questions about Denali Therapeutics
How much does one share of Denali Therapeutics earn?
Over the last 12 months, Denali Therapeutics lost $2.84 for each share.
Does Denali Therapeutics pay a dividend?
Denali Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Denali Therapeutics’s book value per share?
Denali Therapeutics’s book value is $5.23 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Denali Therapeutics have?
Each share of Denali Therapeutics has $5.88 of cash and investments, as of June 30, 2026.
What is Denali Therapeutics’s free cash flow per share?
−$2.42 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Denali Therapeutics bought back shares?
Denali Therapeutics’s share count rose about 2587% from 2016 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.